KRT33A

Across TCGA pan-cancer cohorts, KRT33A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KRT33A data layer compared with 18 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher KRT33A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRT33A expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where KRT33A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.543	0.817	.010	49	view →
PDAC	DFS	Quartile	III,IV	0.375	0.951	.004	18	view →
LUAD	OS	Median	All	0.648	0.864	.005	9	view →
HNSC	OS	Median	IV	0.619	0.809	.039	2	view →
LSCC	DFS	Tertile	III,IV	1.000	0.827	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KRT33A–CCRCC (DFS)

Open the CCRCC breakdown →